Hospira Restructures Following Mayne Pharma Acquisition

PharmaManufacturing.com
02/02/2007

Lake Forest, Ill.-based Hospira, Inc., on Feb. 1 announced it has completed the acquisition of Mayne Pharma Limited, an Australia-based specialty injectable pharmaceuticals company.

The addition of Mayne significantly expands Hospira's global footprint and doubles its international sales to nearly 30 percent of Hospira's total sales. In addition, the acquisition is expected to:

• Expand and solidify Hospira's oncology presence. Specialty oncology products represent roughly half of Mayne's portfolio, which boasts a comprehensive range of agents across this important and fast-growing therapeutic category. Fueled by a significant stream of patent expirations over the next several years, the oncology market is expected to grow faster than the aggregate generic injectables segment.



• Provide Hospira with potent/cytotoxic manufacturing and research and development capabilities. Mayne's comprehensive and differentiated expertise in formulating and manufacturing potent and cytotoxic compounds supplements Hospira's broad development and manufacturing capabilities.



• Continue to help reduce the overall costs of healthcare. By increasing the number of specialty generic injectable drugs in its portfolio and associated manufacturing efficiencies, Hospira will be better positioned to provide high-quality, less costly alternatives to many proprietary pharmaceuticals.

As part of Hospira's continued transformation into a high-performing global organization, the company is implementing a new leadership structure to foster a stronger global perspective, reinforce its connection to customers and establish a solid foundation for future growth.